Cognition Therapeutics

Yahoo Finance • 19 days ago

Pre-Market Earnings Report for March 26, 2026 : CMC, DOO, SCVL, DBI, LOVE, LUCD, ABOS, CGTX, RMTI

The following companies are expected to report earnings prior to market open on 03/26/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Commercial Metals Company (CMC)is reporting for the quarter ending F... Full story

Yahoo Finance • 24 days ago

3 things to look forward to on Monday

[Historic buildings of Wall Street in the financial district of lower Manhattan, New York City] deberarr U.S. stocks closed lower on Friday and ended lower for a fourth consecutive week as oil sustained higher prices despite efforts to mi... Full story

Yahoo Finance • 4 months ago

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that its expanded... Full story

Yahoo Finance • 4 months ago

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

- Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting - - Actively Evaluating Strategy Across DLB and Alzheimer’s Disease - PURCHASE, N.Y., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (th... Full story

Yahoo Finance • 5 months ago

Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference

PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the Company’s president a... Full story

Yahoo Finance • 5 months ago

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease

PURCHASE, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company has r... Full story

Yahoo Finance • 5 months ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

- $30 Million Registered Direct Offering Support Next Stage of Development for Zervimesine (CT1812) - - Aligned with U.S. FDA on Registrational Path for Zervimesine - - Expanded Access Program for Dementia with Lewy Bodies Ongoing - PUR... Full story

Yahoo Finance • 7 months ago

Here are the top movers in Monday's session.

Here are the top movers in Monday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT ATCH [https://www.chartmill.com/stock/quote/ATCH/profile] 148.0% ATLASCLEAR HOLD... Full story

Yahoo Finance • 7 months ago

Which stocks are moving on Monday?

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT ATCH [https:... Full story

Yahoo Finance • 7 months ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target

PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘STA... Full story

Yahoo Finance • 7 months ago

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed its previously annou... Full story

Yahoo Finance • 8 months ago

Wondering what's happening in today's pre-market session?

As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COM... Full story

Yahoo Finance • 8 months ago

Cognition Therapeutics launches $30M share offering

* Cognition Therapeutics (NASDAQ:CGTX [https://seekingalpha.com/symbol/CGTX]) has announced an offering [https://seekingalpha.com/pr/20214045-cognition-therapeutics-announces-30-million-registered-direct-offering-of-common-stock]of 14.7M... Full story

Yahoo Finance • 8 months ago

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

- The offering was made to two new fundamental institutional investors - - The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative disorders - PURCHASE, N.Y., Aug. 27,... Full story

Yahoo Finance • 8 months ago

Cognition Therapeutics regains Nasdaq compliance on $1.00 bid price rule

* Cognition Therapeutics (NASDAQ:CGTX [https://seekingalpha.com/symbol/CGTX]) on Tuesday said that it has regained compliance with Nasdaq's minimum bid price requirement. * The biotech firm received the compliance notification from the... Full story

Yahoo Finance • 8 months ago

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, was notified by The Nasdaq L... Full story

Yahoo Finance • 8 months ago

The market is filled with gapping stocks in Monday's session.

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT HCWB [https://www.chartmill.com/st... Full story

Yahoo Finance • 8 months ago

What's going on in today's session

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT EEIQ [https://www.chartmill.com/stock/quote/EEIQ/profile]... Full story

Yahoo Finance • 8 months ago

Friday's session: top gainers and losers

Here are the top movers in Friday's session, showcasing the stocks with significant price changes. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT EEIQ [https://www.chartmill.com/stock/quote/EEIQ/profile] 137.0% In... Full story

Yahoo Finance • 8 months ago

Thursday's session: top gainers and losers

Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top gainers and losers in today's session. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT TPIC [http... Full story